The advent of next-generation RAS inhibitors brings renewed optimism to the care of patients with pancreatic cancer after decades of failure for novel therapeutics. A recent study highlights the potent antitumour activity of the multi-selective RAS(ON) inhibitor RMC-7977 across a spectrum of preclinical pancreatic cancer models.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).
Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298–311 (2023).
Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160–166 (2023).
Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994–1017 (2024).
Arbour, K. C. et al. 652O preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [abstract]. Ann. Oncol. 34, S458 (2023).
Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927–936 (2024).
Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919–926 (2024).
Mahadevan, K. K. et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 + T cells. Cancer Cell 41, 1606–1620.e8 (2023).
Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531–542 (2024).
Haldar, S. D. et al. Abstract CT036: safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: preliminary analysis from a phase I study. Cancer Res. 83 (Suppl. 8), CT036–CT036 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.S.A. reports clinical research funding and consultant/advisory fees from Revolution Medicines, Mirati Therapeutics and Bristol Myers Squibb. S.D.H. declares no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Haldar, S.D., Azad, N.S. Unlocking the promise of RAS inhibition in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 535–536 (2024). https://doi.org/10.1038/s41575-024-00951-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-024-00951-y
